Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
Each line starts at 100 so growth is directly comparable
| Metric | CRWD | MSFT |
|---|---|---|
| Price | $259.67 | $497.93 |
| Change today | ▼ 1.07% | ▼ 0.53% |
| Market cap | $265.89B | $3.70T |
| Return, 3 months | +53.1% | +41.4% |
| Return, year to date | +121.6% | +3.6% |
| Return, 1 year | +119.6% | -1.0% |
| P/E (TTM) | 6,833.4 | 27.7 |
| P/B | 52.1 | 8.4 |
| P/E percentile vs own 5y | 100th | 23rd |
| Dividend yield | – | 0.71% |
| Revenue growth (YoY, latest qtr) | +25.8% | +17.7% |
| Net profit growth (YoY) | +107.6% | +31.3% |
| Gross margin | 75.2% | 67.9% |
| Operating margin | -2.5% | 46.8% |
| Net margin | 0.8% | 40.3% |
| Return on equity | 1.0% | 34.0% |
| Analyst target vs. price | -3.6% | +15.1% |
| Analyst buy share | 86% | 97% |
| RSI (14) | 68 | 55 |
| 30-day volatility | 84.7% | 21.0% |
| Max drawdown, 1 year | -37.2% | -34.5% |
| Trend read | Strong uptrend | Leaning bullish |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.